Policy, biotech and geroscience converge in DC as longevity science edges further into the American political mainstream.
The annual H-SPAN Summit DC, hosted by the Alliance for Longevity Initiatives (A4LI), will return to Georgetown University’s Capitol Campus this summer, bringing together policymakers, regulators, researchers and biotech companies for three days of discussion centered on the future of aging science and preventive medicine. Running from 29 June to 1 July, the event reflects a noticeable shift in tone within the longevity sector – away from futurist spectacle and toward the practical mechanics of translational science, regulation and public policy.
Now in its third year, the summit arrives at a moment when longevity biotechnology is increasingly intersecting with national healthcare strategy. Companies including BioAge Labs, Retro Biosciences, Life Biosciences, Rubedo Life Sciences, Matter Bio, FibroBiologics and Cyclarity are expected to participate alongside representatives from federal agencies and Capitol Hill, as conversations around aging biology continue to migrate from specialist circles into broader economic and political discourse.
Longevity.Technology: The most interesting signal here may not be any single company, panel or Capitol Hill meeting, but the fact that longevity science is beginning to look politically durable. Aging populations, spiraling healthcare expenditure and the awkward arithmetic of longer working lives are not partisan concerns; biology has, inconveniently for Washington, refused to caucus. The expansion of a bipartisan Longevity Science Caucus suggests that healthspan is moving from the edges of speculative biotech into the machinery of serious policy – and that matters, because capital, biology and regulation are now starting to converge. The US still has a formidable biotech advantage, but advantage is not strategy; China, the Gulf states and parts of Europe are increasingly treating longevity as infrastructure, not indulgence. The real test will be whether this momentum can scale beyond showcases and specialist gatherings into equitable deployment, credible regulatory pathways and preventive health systems that reach ordinary people. H-SPAN’s evolution into something resembling a sober healthcare-policy forum is therefore quietly newsworthy – perhaps even more so than if it had arrived with fireworks, moonshots and the usual promise of living forever next week.
The event’s three-day arc is explicitly built around this institutional transition. Day one will focus on translational science, investment and biotechnology development; day two turns toward regulation, reimbursement and policy frameworks; day three culminates in a Congressional briefing and meetings on Capitol Hill, where A4LI members and industry representatives will engage directly with lawmakers.
That sequencing feels deliberate. Longevity science increasingly faces a challenge not of discovery alone, but of integration – into healthcare systems, regulatory architecture and eventually public health strategy itself. Geroscience has spent years producing compelling laboratory data around the biological drivers of aging; the harder question now concerns implementation. Clinical endpoints, FDA pathways, reimbursement mechanisms and equitable access remain unresolved terrain.
From laboratory to legislature
The summit also builds on growing political momentum around longevity policy in Washington. Since the formation of the bipartisan Congressional Longevity Science Caucus in 2023, additional members of the House of Representatives have joined the effort, including Lori Trahan (MA-3), Sam Liccardo (CA-16), Ro Khanna (CA-17), and Scott Peters (CA-50).
For a field that has spent years trying to live down its associations with Silicon Valley hubris and radical life-extension eccentricity, this bipartisan expansion is a quiet victory. Washington is beginning to realize it can no longer afford to ignore the grim arithmetic of aging demographics, shrinking workforces, and spiraling chronic disease expenditure. By the end of the decade, the sheer panic over health budgets will likely do more to advance longevity policy than the actual science ever could.
The policy-heavy emphasis of this year’s summit reflects those realities. A featured panel on day two will examine regulatory frameworks for aging biology research and the possibility of treating the mechanisms of aging as a central target in chronic disease prevention. Participants are expected to include FDA Acting Chief Lowell M Zeta, alongside ARPA-H Director Dr Alicia Jackson, Dr Viviana Perez (Director of the NIA Division of Aging Biology) and Representative Kevin Mullin of California, whose district sits within the Bay Area’s growing longevity biotech ecosystem.
Notably, the conversation has evolved. Five years ago, many longevity conferences revolved around whether aging could be modified biologically at all. Today, at least within serious scientific and policy circles, the debate is increasingly about how healthcare systems should respond if it can.
Scaling longevity
That shift introduces another question – one perhaps less glamorous than cellular rejuvenation, but considerably more important. Scale.
Preventive longevity medicine is currently a luxury good, siloed inside private clinics, wealthy zip codes, and self-funded patient enclaves. The real bottleneck for both regulators and the industry isn’t whether geroscience works, but whether it can scale. If these interventions can’t break out of the boutique medicine bubble and into mainstream healthcare delivery without collapsing under the weight of cost, regulatory friction, or fragmented evidence, they remain a privilege, not a policy.
It is here that gatherings such as H-SPAN may exert their greatest influence. Not through theatrical declarations about radical lifespan extension, but through the slower and arguably more consequential work of coalition-building – aligning researchers, regulators, investors and legislators around a shared vocabulary for aging biology and prevention.
A different horizon
The irony, of course, is that longevity science has only gone and become respectable. A field once associated with eccentric billionaires, cryonics enthusiasts and breathlessly optimistic PowerPoint decks now finds itself discussing reimbursement models and Congressional engagement beneath the sober architecture of Georgetown University.
Still, that may be the clearest sign yet that the sector is entering a different phase entirely – less theatrical perhaps, but substantially harder to dismiss.
The 2026 H-SPAN Summit DC takes place 29 June – 1 July at Georgetown University’s Capitol Campus. Standard day passes for Days 1 & 2 are priced at $750, while single-day admission is $400. The booking deadline is 15 June. For tailored sponsorship packages CLICK HERE and for the full agenda, speaker details and to register, CLICK HERE.
